He noted that tofacitinib is also being considered for approval by the U.S. Food and Drug Administration for the treatment of psoriasis. "Since this medication suppresses the immune system, it's possible that it may be efficacious in other autoimmune conditions, such as alopecia areata and vitiligo," he reasoned. "This is great news for patients with these conditions, since not many effective treatments are currently available."